MediumCardiologyHeart failure with reduced ejection fractionau-amcau-racp
A 68-year-old man with ischaemic cardiomyopathy (LVEF 30%) presents to clinic with exertional dyspnoea corresponding to NYHA class II. He is currently on low-dose ACE inhibitor and a loop diuretic. According to contemporary heart failure guidelines, which additional class of medication has the strongest evidence for mortality reduction and should be introduced next, assuming no contraindication?